Key facts
- iCoat Medical’s last known valuation is $60.5M (Dec 2023).
- It has raised $9.3M; the latest was Later Stage VC ($860K) in Apr 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for iCoat Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for iCoat Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About iCoat Medical
Developer of clinical-stage therapeutics intended for transplantation and cardiovascular diseases. The company develops novel pharmaceutical products including drugs for kidney, heart, and liver transplants to protect the cell surface from specific damages, and drugs for myocardial infarction, cardiopulmonary bypass, and stroke treatment, enabling healthcare professionals in protecting patients' ischemic cells from attack from the innate immune system.
- Sector
- Healthcare
- HQ
- Stockholm, Sweden
- Founded
- 2018
- Employees
- 4
- Website
- icoatmedical.com/
- Ownership
- Privately Held (backing)
iCoat Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iCoat Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iCoat Medical in its N-PORT filings yet. We sweep new filings monthly.